Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 7Osteoporosis 1Cystadenocarcinoma, Serous 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

trametinib 1liposomal doxorubicin 1Topotecan 1Taxes 1Tamoxifen 1Specimen Handling 1Paclitaxel 1Nivolumab 1Magnetic Resonance Spectroscopy 1Letrozole 1Ipilimumab 1Doxorubicin 1CTLA-4 Antigen 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Cystadenocarcinoma, Serous × Letrozole × Clear all
NCT02101788 2025-11-13

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

National Cancer Institute (NCI)

Phase 2/3 Completed
260 enrolled 20 charts

Cystadenocarcinoma, Serous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡